HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of bone, joint, and vascular-access-associated gram-positive bacterial infections with teicoplanin.

Abstract
Teicoplanin, a glycopeptide antibiotic, was evaluated for safety and efficacy in the treatment of vascular-access-associated bacteremias and of bone and joint infections due to susceptible gram-positive organisms. Of 35 patients enrolled, 26 had osteomyelitis, 8 had vascular-access-associated bacteremias, and 1 had a joint infection. A total of 38 gram-positive isolates were identified: 23 Staphylococcus aureus and 6 coagulase-negative staphylococcus and 9 streptococcus isolates. After at least 6 months of follow-up, 17 patients were evaluable for efficacy: 10 of 14 (71%) with osteomyelitis and 3 of 3 with vascular-access-associated bacteremias had full resolution of their infections. Inadequate debridement, the presence of metal, and inadequate dosing were likely causes of two failures and two relapses in patients with osteomyelitis. For all but two organisms, teicoplanin MICs were less than or equal to 2 micrograms/ml. Patients who responded had median peak and trough serum bactericidal levels at serum dilutions of 1:64 and 1:16; trough levels of teicoplanin in serum were greater than 30 micrograms/ml. Patients did not respond as expected to daily doses of 4 mg/kg of body weight, which consequently were increased to greater than or equal to 15 mg/kg. Audiology testing of 20 patients found 2 with a mild loss of high-frequency hearing; 1 patient complained of tinnitus. Patients tolerated peak levels in serum as high as 127 micrograms/ml and trough levels of 49 micrograms/ml. However, 5 of 18 patients (28%) whose daily dose was greater than or equal to 12 mg/kg developed drug fever and rash and had teicoplanin discontinued. Further study of the antibiotic at such higher doses is needed.
AuthorsR N Greenberg
JournalAntimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 34 Issue 12 Pg. 2392-7 (Dec 1990) ISSN: 0066-4804 [Print] United States
PMID2150908 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Glycopeptides
  • Teicoplanin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents (adverse effects, blood, therapeutic use)
  • Bacterial Infections (drug therapy, microbiology)
  • Biological Assay
  • Blood Bactericidal Activity
  • Bone Diseases (drug therapy, microbiology)
  • Female
  • Glycopeptides (adverse effects, blood, therapeutic use)
  • Gram-Positive Bacteria
  • Hearing Disorders (chemically induced)
  • Humans
  • Joint Diseases (drug therapy, microbiology)
  • Male
  • Middle Aged
  • Osteomyelitis (drug therapy, microbiology)
  • Sepsis (drug therapy, microbiology)
  • Teicoplanin
  • Vascular Diseases (drug therapy, microbiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: